Business

Psychedelic Business Spotlight: November 12

This week in psychedelic business news: two of the biggest players in the industry unveil big data; Numinus Wellness helps...

Largest Psilocybin Therapy Trial Ever Conducted Shows Depressive Symptoms Rapidly Reduce

“A single dose of psilocybin generated a rapid response that lasted up to 12 weeks,” explains principal investigator Dr. David...

Cybin Unveils Data Suggesting Its Novel Psilocybin Analog Is the ‘Superior Molecule’

Pre-clinical studies demonstrated multiple advantages, including less patient variability, faster onset of action, shorter duration of effect, and improved brain...

Psychedelic Business Spotlight: November 5

This week in psychedelic business news: DEA grants Cybin a Schedule I manufacturing license; PharmaTher partners with Revive Therapeutics on...

Why We’re Excited About Compass Pathways’ New Clinical Trial Treating PTSD with Psilocybin

FDA Approves First Clinical Trial Using Naturally Sourced Psychedelics

This trial, using Filament Health's botanical drug candidates, is the first to assess the direct administration of psilocin....

Compass Pathways launching NEW Phase II Clinical Trial to Treat PTSD!!!

Compass Pathways is launching a NEW Phase II clinical trial to treat PTSD!!! The trial will use Comp 360, the...

TRIPP Wants You to ‘Be Here Now,’ With or Without Ram Dass

Psychedelic Spotlight trips with Ram Dass at the 50th anniversary celebration of the spiritual teacher's iconic book....

Can the Psychedelics Boom Go Bust? A Conversation with Cybin Chief Clinical Officer Dr. Alex Belser

"Something that people used to speak about only in whispers is now standard policy," says the psychedelics researcher, with 20...

NEW MindMed MDMA trials, Compass Pathways Patent, Small Pharma DMT Trials Begins | MNMD, CMPS, DMT

NEW MindMed MDMA trials, Compass Pathways Patent, Small Pharma DMT Trials Begins | MNMD, CMPS, DMT What's up psychedelic investors!...